Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. The CS is accountable for implementing the sales strategies for approved products consistent with Corcept’s compliance standards as well as all applicable legal requirements for those key targeted health care providers and hospital systems within an assigned territory.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Education Level
Bachelor's degree
Number of Employees
251-500 employees